Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment by Aggarwal, Rahul & Ryan, Charles J.
Castration-Resistant Prostate Cancer: Targeted Therapies and
Individualized Treatment
RAHUL AGGARWAL,
a CHARLES J. RYAN
b
aDivision of Hematology/Oncology, Department of Medicine, and
bHelen Diller Family Comprehensive
Cancer Center, University of California, San Francisco, California, USA
Key Words. Prostatic neoplasms • Androgen receptor • Signal transduction • Investigational treatments
Disclosures: Rahul Aggarwal: None; Charles J. Ryan: Honoraria: sanofi-aventis, Novartis; Research funding/contracted
research: Cougar Biotechnology, Novartis, ImClone.
The article describes a series of drugs that are in development for prostate cancer and, as such, are, by definition, investigational.
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from
commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer
reviewers.
ABSTRACT
Various molecular mechanisms have been implicated
in the progression from hormone-sensitive to castra-
tion-resistant prostate cancer (CRPC). Novel tar-
geted agents to treat CRPC have been developed that
inhibit either androgen receptor (AR)-mediated sig-
naling (AR antagonists and inhibitors of androgen
synthesis) or non–AR-mediated signaling (inhibitors
of Src, mammalian target of rapamycin, chaperone
proteins, insulin-like growth factor-1 receptor, vas-
cular endothelial growth factor, and endothelin-A re-
ceptor) pathways. However, variable efficacy has
been observed in clinical trials, most likely because of
the biologic heterogeneity of CRPC. To account for
potential differences in disease biology, a more indi-
vidualized approach to treatment, based on genomic
and/orproteomicanalysesofindividualtumors,isbe-
ing investigated. By identifying tumors with a char-
acteristic molecular subtype and assigning treatment
accordingly, it is hoped that a higher proportion of
patients will benefit from targeted therapy. Addition-
ally, lessons learned through the application of these
technologies to prostate cancer may subsequently in-
fluence therapeutic development in other solid tu-
mors. The Oncologist 2011;16:264–275
INTRODUCTION
Althoughmostmenwhodevelopprostatecancerdonotdie
from their disease, those who develop castration-resistant
prostatecancer(CRPC)haveapoorprognosisandaremore
likely to die from complications of metastatic disease than
from comorbid illness. Approved systemic chemotherapies
for CRPC provide limited benefits. Docetaxel, a taxane in-
hibitor of microtubule function, remains the standard first-
line treatment based on two phase III trials that showed a
median survival time of 18–19 months [1, 2]. Efforts are
ongoingtodevelopvarioustherapiestargetingmechanisms
behind tumor progression.
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prostate cancer progression from localized disease that re-
mainssensitivetoandrogendeprivationtoCRPC,thelethal
tumor phenotype. Pathways can be divided into those me-
diated by the androgen receptor (AR) and those without di-
rect agonism of the AR [3]. Novel therapies have been
rationally designed to target molecular pathways involved
in oncogenesis and disease progression although results
from trials have been mixed. The biologic heterogeneity of
CRPC, including potential involvement of AR-mediated or
AR-independent pathways, is a probable cause of the vari-
able responses seen with targeted therapies. Arguably, a
more rational approach could involve determining the bio-
logicstatusofanindividualtumorbeforetherapybyassess-
ing gene expression, hormone metabolism, or signaling
activity, and directing treatment accordingly. This more in-
dividualizedapproachisbeingtestedinearly-phaseclinical
trials.
Here, we highlight several novel therapies for CRPC tar-
geted to AR-mediated or non–AR-mediated pathways that
have recently entered clinical trials, including the molecular
rationale and available clinical data. We also summarize
emerging evidence on the potential of individualized therapy
for CRPC.
TARGETING AR-MEDIATED SIGNALING
Numerous lines of evidence indicate that persistent AR ac-
tivation is an important mediator of disease progression in
CRPC [3, 4]. Proposed mechanisms include: AR gene am-
plification or overexpression; AR gene mutation leading to
promiscuous ligand/cofactor interaction; enhanced AR sig-
nal transduction mediated via coactivators; and endocrine
or autocrine activation of the AR, for example, by adrenal
androgens or intratumoral production of dihydrotestoster-
one (DHT). Established AR-directed approaches include
AR antagonists, for example, bicalutamide and flutamide,
in addition to agents that block the production of AR-acti-
vatinghormones,forexample,ketoconazole(Fig.1).How-
ever, in patients with AR overexpression, traditional AR
antagonists have shown agonistic activity toward the AR
[5], which may explain prostate-specific antigen (PSA) de-
creases that sometimes occur following antiandrogen with-
drawal [6, 7] and the limited additive effects of
Figure 1. The androgen synthesis pathway and actions of inhibitors.
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ing hormone–based therapies [8].
MDV3100 is a novel orally available AR antagonist
with no known agonistic activity that was discovered
throughcompoundscreeninginacellularmodelofprostate
cancer activated by AR overexpression [9]. In a phase I/II
trial,140patientswithprogressiveCRPCweretreatedwith
dosesintherangeof30–600mg/day.Inthechemotherapy-
naïve and postchemotherapy subgroups, respectively, a
50% PSA decline from baseline occurred in 62% and 51%,
a partial response (PR) in soft-tissue tumors evaluable by
the Response Evaluation Criteria in Solid Tumors (RE-
CIST) was achieved in 36% and 12%, stabilized bone dis-
ease at 12 weeks on bone scan occurred in 63% and 51%,
and the median time to radiologic progression was not
reachedand29weeks(47weeksinallpatients)[10].Aran-
domized, placebo-controlled phase III study of MDV3100
monotherapy versus placebo in patients with docetaxel-
pretreated CRPC has completed accrual; a second phase III
studyofMDV3100monotherapyversusplaceboinchemo-
therapy-naïve patients with CRPC has recently opened
(Table 1).
Therapies that decrease androgen production from both
endocrine and autocrine sources are also being developed.
Abiraterone acetate is a selective and irreversible inhibitor
of cytochrome P450 (CYP450)c17, an enzyme involved in
androgen synthesis from both adrenal and other sources.
Encouraging activity and safety with abiraterone were seen
in phase I studies [11, 12]. In a phase II trial of 47 patients
with CRPC with prior docetaxel therapy, 50% PSA de-
clines were achieved with abiraterone in 51% of patients,
and among the 30 patients who had RECIST-evaluable tu-
mors, 27% had a PR [13]. In a phase II study of abiraterone
plus prednisone in patients with CRPC and prior chemo-
therapy failure (n  58), 50% PSA declines occurred in
55% of patients who were ketoconazole naïve, versus 30%
of those who had received prior ketoconazole, and the me-
dian times to PSA progression were 198 days and 99 days,
respectively [14]. Also, in a study of abiraterone plus pred-
nisone in patients without prior chemotherapy or ketocona-
zole treatment (n  33), a 50% PSA decline was achieved
by79%ofpatientsandthemediantimetoPSAprogression
was71weeks[15].InaphaseIIIrandomized,double-blind,
placebo-controlled trial of 1,195 metastatic CRPC patients
previously treated with docetaxel, abiraterone plus predni-
sone led to a longer overall survival time than with treat-
mentwithprednisoneplusplacebo(medianoverallsurvival
time,14.8versus10.9months;hazardratio[HR],0.65;p
.0001) [16]. A second phase III trial of abiraterone in
asymptomatic or mildly symptomatic men with metastatic
CRPC who had not received prior chemotherapy has com-
pleted accrual, with final results pending data maturity
(Table 1).
TAK-700isanovelCYP450c17inhibitorsimilartoabi-
raterone. In preliminary data from a phase I/II study in pa-
tients with asymptomatic metastatic CRPC, TAK-700 was
well tolerated and preliminary evidence of activity was
seen, including 50% PSA declines in 12 of 15 patients who
received doses 300 mg twice daily for 3 months [17].
Conversion of testosterone to the more potent DHT by
5-reductase can occur within tumor tissue and is a mech-
anism for continued AR activation. Dutasteride, a dual-
isoform 5-reductase inhibitor, was evaluated in several
phase II trials. In a study of 25 evaluable patients with
asymptomatic CRPC, two had a confirmed 50% PSA de-
clineandninehadstabledisease(SD)for2.5–9months(de-
fined by PSA, RECIST, bone scan, and symptomatic
criteria) [18]. Dutasteride plus ketoconazole and hydrocor-
tisone was also studied in 57 patients with CRPC, resulting
in a 50% PSA response in 56% of patients and median time
to progression (TTP) of 14.5 months [19]. If antitumor ef-
fects are to be seen with dutasteride, it is likely that a dose
0.5 mg/day used in benign prostatic hypertrophy will be
required.
Paradoxically, preclinical studies have shown that tes-
tosterone, if given at a high enough dose, caused regression
of an androgen-independent prostate cancer cell line [20].
In a prior phase I trial of exogenous testosterone adminis-
tered at three times the normal dose to 12 men with CRPC,
treatmentwaswelltolerated,anda50%PSAdeclinewas
observed in one patient [21]. In order to block peripheral
conversion to DHT and potentially increase serum testos-
terone levels and the therapeutic effect, dutasteride was
added to high-dose exogenous testosterone and is currently
being studied in an ongoing phase II trial.
HE3235, a structurally related synthetic analog of an-
drostenediol, an adrenal androgen, has shown preclinical
activity against CRPC cells and xenografts. In preclinical
models of LNCaP cell lines exposed to the combination of
HE3235 and either DHT or androstenediol, there was
greater AR activity and PSA expression. Parodoxically,
however, the addition of HE3235 led to inhibition of tumor
formation/growth in xenograft studies, likely through in-
ducing a proapoptotic effect on tumor cells [22]. Phase I
studies have determined that HE3235 is well tolerated
across a range of doses, and phase II studies are under way
[23].
TARGETING NON–AR-MEDIATED SIGNALING
In addition to AR-mediated pathways, evidence suggests
that several alternative signaling pathways may also be in-
volved in prostate cancer disease progression. Whether or
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Target Agent Phase Design Population Primary endpoint
Estimated n
of patients
ClinicalTrials.
gov identifier
Androgen
synthesis
(CYP17)
Abiraterone and
prednisone
III Randomized, placebo
controlled
Metastatic CRPC after
docetaxel failure
OS 1,158 NCT00638690
Abiraterone and
prednisone
III Randomized, placebo
controlled
Asymptomatic or mildly
symptomatic CRPC
OS, PFS 1,000 NCT00887198
Abiraterone and
prednisone
II Single arm Metastatic CRPC Hormonal effects 60 NCT00544440
TAK-700 II Single arm Chemotherapy-naïve
nonmetastatic CRPC
PSA 42 NCT01046916
TAK-700 I/II Dose ranging Chemotherapy-naïve
metastatic CRPC
Safety 100 NCT00569153
TAK-700 plus
docetaxel and
prednisone
I/II Dose ranging Chemotherapy-naïve
metastatic CRPC
MTD, PK, PSA
response
40 NCT01084655
5-reductase Dutasteride plus
testosterone
II Single arm Metastatic CRPC PFS 30 NCT00853697
Androgen analog
(androstenediol)
HE3235 I/II Dose ranging Metastatic CRPC after
taxane failure
Safety, PK, activity 122 NCT00716794
Androgen
receptor
MDV3100 III Randomized, placebo
controlled
CRPC after docetaxel
failure
OS 1,200 NCT00974311
MDV3100 III Randomized, placebo
controlled
Chemotherapy-naïve
metastatic CRPC
OS, PFS 1,680 NCT01212991
BCL-2, BCL-XL,
MCL-1
AT-101 and
docetaxel
II Randomized, placebo
controlled
Chemotherapy-naïve
metastatic CRPC
OS 220 NCT00571675
Clusterin
(chaperone
protein)
Custirsen plus
docetaxel and
prednisone
III Randomized, placebo
controlled
Chemotherapy-naïve CRPC OS 800 (Planned)
Custirsen plus
docetaxel and
prednisone
III Randomized, placebo
controlled
Metastatic CRPC after
docetaxel failure
Pain palliation 292 NCT01083615
CTLA-4 Ipilimumab III Randomized, placebo
controlled
Metastatic CRPC after
docetaxel failure
OS 800 NCT00861614
Ipilimumab III Randomized, placebo
controlled
Asymptomatic or mildly
symptomatic CRPC
OS 600 NCT01057810
Endothelin A
receptor
Atrasentan plus
docetaxel and
prednisone
III Randomized, placebo
controlled
Chemotherapy-naïve
metastatic CRPC
OS, PFS 930 NCT00134056
Zibotentan III Randomized, placebo
controlled
Chemotherapy-naïve
nonmetastatic CRPC
OS, PFS 1,500 NCT00626548
Zibotentan III Randomized, placebo
controlled
Asymptomatic or mildly
symptomatic CRPC with
bone metastases
OS 848 NCT00554229
Zibotentan plus
docetaxel
III Randomized, placebo
controlled
Chemotherapy-naïve
metastatic CRPC
OS 1,445 NCT00617669
IGF-1R Cixutumumab plus
mitoxantrone and
prednisone
II Randomized, open label
versus IMC-1121B
Metastatic CRPC after
failure on docetaxel-based
chemotherapy
PFS 132 NCT00683475
Figitumumab plus
docetaxel and
prednisone
II Single arm Chemotherapy-naïve or
docetaxel-refractory CRPC
PSA, tumor
response
120 NCT00313781
IGF-1R, mTOR Cixutumumab plus
temsirolimus
I/II Single arm Chemotherapy-naïve
metastatic CRPC
Tumor response,
time to progression
48 NCT01026623
mTOR Everolimus II Single arm Metastatic or locally
advanced CRPC that is not
progressing rapidly
PFS 39 NCT00976755
Everolimus plus
docetaxel and
prednisone
I/II Single arm Metastatic CRPC Safety, tumor
response
60 NCT00459186
Everolimus plus
bicalutamide
II Randomized, placebo
controlled
Metastatic or recurrent
CRPC
PSA response 80 NCT00814788
Everolimus II Molecular, genetic, and
genomic assessments of
mTOR inhibition
Metastatic CRPC mTOR inhibition 60 NCT00636090
Temsirolimus II Single arm Chemotherapy-naïve CRPC Tumor response 24 NCT00919035
Ridaforolimus plus
bicalutamide
II Randomized, placebo
controlled
Asymptomatic metastatic
CRPC
PSA response,
dose-limiting
toxicities
156 NCT00777959
(continued)
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downstreamcomponentsofARsignalinghasnotbeenfully
elucidated,butthismayvarybypathway.Severalpathways
thatareacurrentfocusforresearchwithtargetedagentsare
discussed below (Fig. 2).
Src Pathway
SrcandothermembersoftheSrc-familykinases(SFKs)are
nonreceptor tyrosine kinases that transduce signals from a
range of upstream proteins, including receptors for epider-
mal growth factor (EGF), platelet-derived growth factor
(PDGF), and vascular endothelial growth factor (VEGF)
[24]. In addition to the established role of growth factor re-
ceptors in prostate cancer oncogenesis, preclinical studies
have shown that Src and SFKs are highly active and/or
overexpressedduringprostatetumorgrowthandmetastasis
[25].Srcisalsorequiredduringosteoclastfunctioning[26].
In a recent study of tumor samples from patients with
CRPC, SFK activity was elevated in approximately 30% of
cases and patients with greater SFK activity had a signifi-
cantly shorter overall survival duration [27].
Dasatinib is a potent inhibitor of Src and SFKs that has
shown preclinical antitumor and antimetastatic activity
against prostate cancer cells and antiosteoclast activity
[28–31]. In a phase II trial of dasatinib monotherapy in 47
patients with metastatic chemotherapy-naïve CRPC, 6%
had a 50% reduction in PSA, 12 of 23 patients (52%) with
RECIST-evaluable disease had SD, and 23 of 41 patients
(49%) with bone metastases at baseline had no new bone
lesions at week 12 [32]. In a phase I/II study of dasatinib
plus docetaxel and prednisone in chemotherapy-naïve pa-
tients with CRPC, 49% had a 50% PSA decline and 58% of
Table 1. (Continued)
Target Agent Phase Design Population Primary endpoint
Estimated n
of patients
ClinicalTrials.
gov identifier
mTOR, VEGF Temsirolimus plus
bevacizumab
I/II Dose ranging Metastatic CRPC after
chemotherapy failure
MTD, composite
response
34 NCT01083368
RANKL Denosumab III Randomized, placebo
controlled versus
zoledronic acid
CRPC with bone metastases Time to skeletal-
related event
1,904 NCT00321620
Denosumab III Randomized, placebo
controlled
Nonmetastatic CRPC Time to bone
metastasis
1,435 NCT00286091
Src Dasatinib plus
docetaxel and
prednisone
III Randomized, placebo
controlled
Chemotherapy-naïve
metastatic CRPC
OS 1,380 NCT00744497
Dasatinib or
nilutamide
II Genomic-guided therapy Metastatic CRPC PFS 60 NCT00918385
Saracatinib II Randomized versus
zoledronic acid
Recurrent or progressive
prostate or breast cancer
with bone metastases
Bone markers 132 NCT00558272
VEGF Bevacizumab plus
docetaxel and
prednisone
III Randomized, placebo
controlled
Chemotherapy-naïve CRPC OS 1,020 NCT00110214
Bevacizumab plus
lenalidomide plus
docetaxel and
prednisone
II Single arm Metastatic
chemotherapy-naïve CRPC
Safety 57 NCT00942578
Aflibercept (VEGF
trap) plus docetaxel
and prednisone
III Randomized, placebo
controlled
Metastatic
chemotherapy-naïve CRPC
OS 1,200 NCT00519285
VEGFR Cediranib II Single arm Metastatic
chemotherapy-naïve CRPC
after docetaxel failure
PFS 62 NCT00436956
Cediranib plus
docetaxel and
prednisone
II Randomized versus
docetaxel/prednisone
Chemotherapy-naïve CRPC PFS 104 NCT00527124
VEGFR, PDGFR,
Kit
Sunitinib plus
prednisone
III Randomized, placebo
controlled versus
prednisone
Metastatic CRPC after
docetaxel failure
OS 819 NCT00676650
Sunitinib II Single arm Metastatic CRPC after
docetaxel failure
PFS 50 NCT00748358
VEGFR, PDGFR,
RAF, Kit
Sorafenib plus
docetaxel
II Single arm Metastatic
chemotherapy-naïve CRPC
PSA response 69 NCT00589420
Abbreviations: BCL, B-cell lymphoma; CTLA-4, cytotoxic T-lymphocyte antigen 4; CRPC, castration-resistant prostate
cancer; CYP, cytochrome P450; IGF-1R, insulin-like growth factor-1 receptor; MCL-1, myeloid cell leukemia sequence 1;
MTD, maximum-tolerated dose; mTOR, mammalian target of rapamycin; OS, overall survival; PDGFR, platelet-derived
growth factor receptor; PFS, progression-free survival; PK, pharmacokinetics; PSA, prostate-specific antigen; RANKL,
receptor activator for nuclear factor B ligand; VEGFR, vascular endothelial growth factor receptor.
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reductioninthesizeand/ornumberoflesionsin28%ofpa-
tients and no new lesions in 69% of patients [33]. These
findings led to a randomized, placebo-controlled phase III
trial of dasatinib plus docetaxel.
Saracatinib (AZD0530) is another oral Src inhibitor in
clinical development. In preclinical studies, saracatinib
blocked proliferation and migration in a range of prostate
cancer cell lines, including androgen-independent xeno-
grafts [34–36]. Saracatinib has also shown antiosteoclast
activity in vitro and in vivo [37, 38]. In an initial phase II,
single-arm, Simon two-stage trial of saracatinib mono-
therapyinpatientswithadvancedCRPC,fiveof28patients
had a slight decline in PSA, though no patient achieved a
30%decline.Themedianprogression-freesurvivalinterval
was 8 weeks [39].
Phosphoinositide-3-Kinase–Akt–Mammalian
Target of Rapamycin Pathway
Upregulation of the phosphoinositide-3-kinase (PI3K)–
Akt–mammaliantargetofrapamycin(mTOR)pathwayhas
been detected in various tumors, including prostate cancer
[40]. PI3K is activated by several extracellular receptors,
includingEGFreceptorandinsulin-likegrowthfactor-1re-
ceptor (IGF-1R), in addition to intracellular oncogenes
such as RAS [41]. In turn, activated PI3K induces Akt to
phosphorylate and activate mTOR, which promotes cell di-
vision. PI3K activation is regulated by tumor suppressor
phosphataseandtensinhomolog(PTEN),andlossofPTEN
function has been detected in prostate cancer [42–44]. Pre-
clinical studies suggest that loss of PTEN function and/or
activation of the PI3K–Akt–mTOR pathway can result in
androgen-independent prostate cancer growth [45, 46].
Furthermore, deletion of PTEN has been associated with
earlier disease progression in patients with prostate cancer
[47, 48] and greater AR expression and cancer-associated
mortality in patients with CRPC [49].
Several mTOR inhibitors have been developed. In
mouse studies, everolimus (RAD001) inhibited the growth
ofprostatecancercellsinboneandeffectswereaugmented
by combination treatment with docetaxel and zoledronic
acid [50]. In a phase I dose-escalation trial of everolimus
plus docetaxel in chemotherapy-naïve patients with meta-
static CRPC and a positive fluorodeoxyglucose positron
emission tomography scan, there were no dose-limiting
toxicities. Of 14 evaluable patients, 10 had metabolic SD
and four had a metabolic PR [51]. In a phase I trial of
everolimus plus docetaxel and bevacizumab in patients
with metastatic, chemotherapy-naïve CRPC, 50% PSA de-
clines were seen in 10 of 12 patients [52]. In a phase II,
Figure 2. Molecular targets of agents being investigated for the treatment of castration-resistant prostate cancer.
Abbreviations: AR, androgen receptor; BCL-2, B-cell lymphoma 2; EGFR, epidermal growth factor receptor; HSP90, heat-
shock protein 90; IGF-1R, insulin-like growth factor-1 receptor; mTOR, mammalian target of rapamycin; PDGFR, platelet-
derived growth factor receptor; PI3K, phosphoinositide-3-kinase; VEGF, vascular endothelial growth factor; VEGFR, VEGFR
receptor.
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therapy in 19 patients with CRPC, most of whom were do-
cetaxelrefractory,themedianTTPwas85daysandnoPSA
or tumor responses were recorded [53]. In preclinical stud-
ies, temsirolimus (CCI-779) inhibited the growth of pros-
tate cancer cell lines and xenografts, and had greater
activityincombinationwithdocetaxel[54,55].Inaddition,
phase I studies of ridaforolimus (AP23573) in patients with
advanced solid tumors have successfully been completed
[56,57].Asingle-arm,phaseIItrialofridaforolimusmono-
therapy in taxane-resistant CRPC patients has completed
enrollment and results are pending (ClinicalTrials.gov
Identifier, NCT00110188). Clinical studies with everoli-
mus,temsirolimus,andridaforolimusinCRPCaresumma-
rized in Table 1.
Chaperone Proteins
Chaperone (heat-shock) proteins have antiapoptotic prop-
erties and are an established target for anticancer therapy.
Although heat-shock protein 90 (HSP90) was an early fo-
cus for study, no HSP90 inhibitor has so far proved to be
therapeutically viable for prostate cancer, although work is
ongoing[58].Clusterin,analternativechaperoneprotein,is
a novel target. In prostate cancer cell lines, clusterin over-
expression resulted in androgen-independent growth [59]
and clusterin gene silencing induced apoptosis and signifi-
cantlyreducedgrowth[60].Clusterinexpressionisupregu-
lated in patients with prostate cancer who have received
androgen-deprivation therapy (ADT) [61].
Custirsen (OGX-011) is an antisense inhibitor of clus-
terin that suppresses clusterin expression in tumor tissue
when administered to patients with localized prostate can-
cer [62]. In vitro, custirsen was found to resensitize do-
cetaxel-refractory prostate cancer cell lines to docetaxel
[63]. A randomized phase II study of docetaxel plus pred-
nisone with or without custirsen in patients with metastatic
CRPC (n  82) has been completed, and showed a longer
median overall survival time in the custirsen arm (24
months versus 17 months; HR, 0.61; p  .06), although
rates of PSA and tumor response were similar [64]. Based
on these findings, phase III trials of OGX-011 plus do-
cetaxel and prednisone are planned.
IGF-1R Pathway
IGF-1R has antiapoptotic and transforming activities, and
IGF-1R–mediated signaling can be detected during several
stages of metastasis, including adhesion, migration, and in-
vasion [65]. In vitro models suggest that increased IGF-1R
expression in prostate cancer cells can lead to androgen in-
dependence [66, 67]. In a recent study using frozen tissue
specimens, IGF-1R was more frequently expressed in stro-
maltissuesurroundingmalignantthansurroundingnonma-
lignant tissue and in high-grade than in low-grade tumors
[68]. Studies of IGF-1R ligands have provided further evi-
dencefortheoncogenicroleofIGFsignaling.Intransgenic
mice expressing human IGF-1 in the basal prostate epithe-
lium, spontaneous tumorigenesis was seen [69]. In a study
of prostatic tumor tissue, expression of IGF-1 and IGF-2
was higher in high-grade than in low-grade tumors [70].
Furthermore,inameta-analysisofclinicalstudies,elevated
circulating concentrations of IGF-1 were associated with a
greater risk for prostate cancer [71].
Three monoclonal antibodies against IGF-1R, cixutu-
mumab (IMC-A12), figitumumab (CP-751,871), and
AMG-479, are being assessed in CRPC patients and have
demonstrated good tolerability in phase I studies [72–75].
InaphaseIIstudyofcixutumumabinmenwithasymptom-
atic metastatic CRPC, nine of 31 patients achieved SD for
6 months (range, 7.4–12.5 months) [76]. Further studies
of IGF-1R antibodies are in progress (Table 1). The devel-
opmentoffigitumumabwassuspendedafteranunexpected
finding of a higher treatment-related mortality rate when
this agent was added to standard chemotherapy.
VEGF
VEGF, stimulated by such factors as hypoxia, low pH, and
growth factor receptors, plays a key role in promoting an-
giogenesis and tumor progression in various tumor types.
VEGFexpressionhasbeenfoundinbothlocalizedandmet-
astaticprostatecancerspecimens,andhigherplasmaVEGF
levels have been correlated with disease severity [77] In
preclinical models, antibodies directed against VEGF in-
hibited the growth of prostate cancer tumors [78].
Bevacizumab, a humanized monoclonal antibody di-
rected against VEGF, has been evaluated in prostate cancer
inseveralclinicaltrials.InaphaseIItrialof15patientswith
CRPC, after 12 weeks of therapy with bevacizumab dosed
at 10 mg/kg every 2 weeks, no patients experienced an ob-
jective response or PSA decline 50% [79]. In a random-
ized, double-blind, placebo-controlled phase III trial of
docetaxel plus prednisone with or without bevacizumab in
1,050 men with chemotherapy-naïve CRPC, the median
overall survival time was not significantly longer with the
addition of bevacizumab; however, the median progres-
sive-free survival interval was longer—7.5 months in the
control arm and 9.9 months in the bevacizumab-containing
arm (stratified log-rank p-value .0001) [80].
Aflibercept,aVEGFtrapconsistingoftheFcportionof
human IgG1 fused to the extracellular ligand-binding do-
main of VEGF receptor (VEGFR)-1 and VEGFR-2, is cur-
rently being evaluated in a placebo-controlled, randomized
270 CRPC: Targeted Therapies and Individualized Treatmentphase III trial in combination with docetaxel plus predni-
sone (ClinicalTrials.gov Identifier, NCT00519285).
Sunitinib, a small molecular tyrosine kinase inhibitor of
VEGFR-1 to VEGFR-3, along with multiple other recep-
tors including PDGF receptor (PDGFR)- and PDGFR-,
inhibits angiogenesis and has shown promising activity in
prostate cancer, especially in the postdocetaxel setting. In a
single-arm, phase II trial of sunitinib in 36 men with meta-
static CRPC previously treated with docetaxel, seven pa-
tients (21.2%) had a PSA decline 30% and two patients
had an objective response [81]. A phase III trial, however,
of sunitinib plus prednisone versus placebo plus predni-
sone,inmenwithCRPCandpriordocetaxelandwithapri-
mary endpoint of overall survival, was terminated
prematurelyasaresultoffutilityinSeptember2010(Clini-
calTrials.gov Identifier, NCT00676650).
Endothelin
The endothelin family of peptides, mediated mostly by endo-
thelin-1 binding to the endothelin-A receptor, modulates va-
somotor tone, nociception, and cellular proliferation in a
variety of tissues [82]. Endothelin-1 acts via the endothelin-A
receptor to promote prostate cancer progression via several
mechanisms, including acting as a mitogen for both prostate
cancer cells and osteoblasts, which are responsible for the os-
teoblastic metastatic lesions common in metastatic prostate
cancer [83, 84]. Selective endothelin-A receptor antagonists
block the proliferation of prostate cancer cells and osteoblasts
in the presence of exogenous endothelin [84].
Atrasentan is a potent and highly selective inhibitor of the
endothelin-A receptor, and was shown in a randomized phase
II trial, at a dose of 10 mg/day, to produce a trend towards a
longerTTPthanwithplaceboinastudyof288menwithmet-
astatic CRPC (median TTP, 183 days versus 137 days; p 
.13) [85]. However, two subsequent, randomized, placebo-
controlled, phase III trials of men with either nonmetastatic or
metastatic CRPC failed to demonstrate a significantly longer
time to disease progression in patients treated with atrasentan
than in those treated with placebo [86, 87]. A randomized
phase III trial comparing prednisone plus docetaxel with or
without atrasentan has finished accrual, with final results
pending (ClinicalTrials.gov Identifier, NCT00134056).
Zibotentanisanonpeptide,orallybioavailableselective
inhibitorofendothelin-Areceptorthatwaswelltoleratedin
aphaseItrial,withamaximum-tolerateddoseof15mg/day
[88]. In a randomized, phase II trial with three treatment
arms consisting of men with metastatic CRPC treated with
zibotentan 10 mg/day, zibotentan 15 mg/day, or placebo,
theprimaryendpointofalongertimetodiseaseprogression
was not significant; however, there was a trend toward lon-
geroverallsurvivalinbothzibotentanarms,comparedwith
placebo, with a median follow-up of 22 months (HR, 0.76;
p  .103 for the 15-mg arm. HR, 0.83; p  .254 for the
10-mg arm) [89]. Based on these results, three phase III tri-
als of zibotentan in men with CRPC are ongoing (Table 1).
INDIVIDUALIZED TARGETED THERAPY FOR CRPC
Individual Tumor Gene/Protein Expression to
Guide Therapy
Becauseofbiologicalheterogeneity,includingthepotential
for continuing AR-mediated signaling or androgen inde-
pendence, it is likely that no single agent will be uniformly
effective for treating CRPC. This hypothesis is supported
by the variable efficacy observed in clinical trials of the se-
lectednovelagentsoutlinedabove.Amoreindividualizedand
arguably more rational approach to treatment is currently be-
ing investigated in CRPC, which involves using genomic and
proteomic analyses to assess the involvement of specific mo-
lecular pathways. The aim is to tailor treatment based on indi-
vidual tumor characteristics and thereby select patients who
are most likely to respond to different therapies. The benefits
of individualized therapy have already been demonstrated in
other tumor types, particularly in breast cancer using human
epidermal growth factor receptor 2 testing and trastuzumab
therapy. Predictive markers of response to secondary hor-
monal therapy in CRPC have already been identified. For ex-
ample, CRPC tumors with AR gene amplification respond
better to secondary hormone therapy (combined androgen
blockade) than tumors without AR amplification [90].
Recent studies in CRPC have further evaluated a
genomic-guided approach to treatment [91]. Using an an-
drogen-sensitive prostate cancer cell line (LNCaP), a tran-
scription signature for AR activity was identified, which
wasconfirmedtoberobustinindependentdatasetsofpros-
tate cancer cell lines and human tumors. When the AR sig-
nature was investigated in patient samples, AR activity was
generally higher in localized, untreated tumors and lower
after neoadjuvant hormone therapy and in CRPC, seem-
ingly representing declining AR activity with prostate can-
cer progression. However, AR activity was heterogeneous
in CRPC patients, with approximately one third of patient
samples showing persistent AR activity, which could help
to explain the variable responses to AR-directed therapies
observedintrials.Toidentifynoveltherapeuticoptionsthat
may be most useful for patients with low AR activity, sam-
pleswerecomparedwithpublishedsignaturesforothermo-
lecular targets [91–93]. Of those tested, the signature for
Src activity most consistently correlated with low AR activ-
ity, both in localized (p  .0071) and metastatic (p  .0033)
disease. Similarly, low AR activity correlated with a signal
predicting sensitivity to the Src inhibitor dasatinib (p.019).
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AR activity detected in tumor samples might benefit more
from Src inhibitor treatment than AR-directed therapy.
A prospective study is now in progress to test a genom-
ic-guided approach to treatment (ClinicalTrials.gov Identi-
fier, NCT00918385). Patients with metastatic CRPC will
beprescreenedandthosewithtumorswithhighARactivity
will receive nilutamide, an AR-targeted agent, whereas
those with low AR activity will be treated with dasatinib.
Patients failing single-agent treatment will receive combi-
nation therapy. A study is also being performed with
everolimus that will examine gene expression profiles and
molecular characteristics in patients with CRPC to deter-
mine any possible association with treatment responses,
which could potentially inform a future genomic-guided
trial (ClinicalTrials.gov Identifier, NCT00636090).
A key question in the development of genomic-guided
clinical trials centers around the type of specimen that is
used to molecularly define an individual patient’s tumor.
Prior comprehensive gene expression analyses that com-
pared localized prostate cancers with metastatic tumors
found wide variability in the expression of various subsets
of genes, including those involved in cell cycling, cell ad-
hesion, and signal transduction [94]. Given the molecular
heterogeneity of prostate cancer, there has been consider-
able interest in developing techniques to molecularly char-
acterize metastatic prostate cancer tissue rather than
specimens obtained from prior prostate biopsies or prosta-
tectomy specimens containing localized prostate cancer. In
the aforementioned phase II trial of nilutamide and dasat-
inib (ClinicalTrials.gov Identifier, NCT00918385), fresh
tissueobtainedviabiopsyofametastaticsitewillbeusedto
molecularly characterize a patient’s tumor.
Circulating tumor cells (CTCs) potentially represent an
alternative, less invasive means to obtain gene expression
data. Techniques to identify and isolate these cells with in-
creasing sensitivity and purity are actively being refined
[95]. Enumeration of the number of CTCs pre- and postini-
tiationofchemotherapywasshowntobepredictiveofover-
all survival in a prospective study [96]. Needed, however,
are refinements in techniques used to not only count, but
also to characterize, CTC gene expression profiles, as well
as studies that compare molecular profiles among CTCs,
primarytumorsamples,andmetastaticsiteswithinindivid-
ual patients to assess for concordancy (or lack thereof) in
gene expression over time and location.
Pharmacogenetic Profiling
Recent data have established that pharmacogenomic fac-
tors, that is, genetic polymorphisms affecting proteins in-
volved in drug metabolism or action, may play a role in
determining response to targeted therapies, both in prostate
cancerandothersolidtumors.Forexample,among529pa-
tients undergoing ADT, polymorphisms in three separate
genes involved in hormone synthesis (CYP19A1, HSD3B1,
andHSD17B4)weresignificantly(p.01)associatedwith
a longer TTP, and best responses were observed in patients
with more than one polymorphism [97]. Furthermore, sur-
vival on docetaxel in patients with CRPC has been associ-
ated with specific genotypes of ABCB1 (encoding a drug
efflux protein) and CYP1B1 (encoding an enzyme involved
in estrogen metabolism) [98, 99]. Tailoring therapy based
onpharmacogenomicparametersislikelytobetestedinfu-
ture prospective studies.
CONCLUSIONS
Traditional drug discovery methods have identified several
potential molecular targets for treating CRPC, including
those that inhibit AR-mediated and non–AR-mediated sig-
naling.Inrecentyears,novelagentshaveshownpromisein
clinical trials, including agents targeting the androgen axis
(e.g., novel AR antagonists and inhibitors of androgen pro-
duction) and agents with other targets (e.g., Src, IGF-1R,
mTOR, and clusterin). However, it is becoming increas-
ingly apparent that CRPC is a heterogeneous disease and
patient subgroups are likely to exist that are characterized
by the involvement of different signaling pathways in dis-
ease progression to different degrees. This suggests that a
more rational/individualized approach is required to maxi-
mize potential benefits from targeted therapy. Using
genomic signatures, a recent study showed that patients
with low AR activity are more likely to have high Src ac-
tivityandsensitivitytodasatinib,andanongoingstudywill
provideaninitialtestofwhethergenomic-guidedtreatment
can increase response rates. Identifying patient populations
with a specific molecular subtype should hopefully im-
prove the chances of treatment response, and ultimately, a
scenario could be envisaged in which patients receive per-
sonalized targeted therapy based on their genomic profile,
using both the “real-time” tumor genotype/phenotype and
the pharmacogenetic profile of the patient. Discoveries in
CRPC could translate to other advanced cancers.
AUTHOR CONTRIBUTIONS
Conception/Design: Rahul Aggarwal, Charles J. Ryan
Data analysis and interpretation: Rahul Aggarwal, Charles J. Ryan
Manuscript writing: Rahul Aggarwal, Charles J. Ryan
Final approval of manuscript: Rahul Aggarwal, Charles J. Ryan
The authors take full responsibility for the content of this publication but thank
Jeremy Gardner, Ph.D. (StemScientific), funded by Bristol-Myers Squibb, for
providing assistance with copyediting, literature searching, and figure/table
preparation. Bristol-Myers Squibb did not influence the content of the manu-
script, nor did the authors receive financial compensation.
272 CRPC: Targeted Therapies and Individualized TreatmentREFERENCES
1 Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mi-
toxantrone plus prednisone for advanced prostate cancer. N Engl J Med
2004;351:1502–1512.
2 Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine
compared with mitoxantrone and prednisone for advanced refractory pros-
tate cancer. N Engl J Med 2004;351:1513–1520.
3 Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate can-
cer: Locking up the molecular escape routes. Clin Cancer Res 2009;15:
3251–3255.
4 Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway
in prostate cancer. Curr Opin Pharmacol 2008;8:440–448.
5 Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance
to antiandrogen therapy. Nat Med 2004;10:33–39.
6 SmallEJ,HalabiS,DawsonNAetal.Antiandrogenwithdrawalaloneorin
combination with ketoconazole in androgen-independent prostate cancer
patients: A phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025–
1033.
7 Sartor AO, Tangen CM, Hussain MH et al. Antiandrogen withdrawal in
castrate-refractory prostate cancer: A Southwest Oncology Group trial
(SWOG 9426). Cancer 2008;112:2393–2400.
8 Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-
analysis of monotherapy compared with combined androgen blockade for
patients with advanced prostate carcinoma. Cancer 2002;95:361–376.
9 Tran C, Ouk S, Clegg NJ et al. Development of a second-generation anti-
androgen for treatment of advanced prostate cancer. Science 2009;324:
787–790.
10 Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in
castration-resistant prostate cancer: A phase 1–2 study. Lancet 2010;375:
1437–1446.
11 Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhib-
itor of CYP17, abiraterone acetate, confirms that castration-resistant pros-
tate cancer commonly remains hormone driven. J Clin Oncol 2008;26:
4563–4571.
12 Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 in-
hibitor abiraterone acetate demonstrating clinical activity in patients with
castration-resistant prostate cancer who received prior ketoconazole ther-
apy. J Clin Oncol 2010;28:1481–1488.
13 Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor
activity in post-docetaxel, castration-resistant prostate cancer with the
CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489–1495.
14 Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abi-
raterone acetate plus prednisone therapy in patients with docetaxel-treated
castration-resistant prostate cancer. J Clin Oncol 2010;28:1496–1501.
15 RyanCJ,SmithMR,LogothetisCetal.Mediantimetoprogressioninche-
motherapy-naive patients with castration-resistant prostate cancer treated
with abiraterone acetate and low-dose prednisone [abstract 4671]. J Clin
Oncol 2010;28(15 suppl):384s.
16 de Bono JS, Logothetis CJ, Fizazi K et al. Abiraterone acetate (AA) plus
low dose prednisone (P) improves overall survival (OS) in patients (Pts)
with metastatic castration resistant prostate cancer (MCRPC) who have
progressed after docetaxel-based chemotherapy: Results of COU-AA-301,
a randomized double-blind placebo-controlled phase III study. Ann Oncol
2010;21(suppl 8):LBA5.
17 Dreicer R, Agus DB, MacVicar GR et al. Safety, pharmacokinetics, and
efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A
phase I/II, open-label study [abstract 3084]. J Clin Oncol 2010;28
(15 suppl):254s.
18 Shah SK, Trump DL, Sartor O et al. Phase II study of dutasteride for recur-
rent prostate cancer during androgen deprivation therapy. J Urol 2009;181:
621–626.
19 Taplin ME, Regan MM, Ko YJ et al. Phase II study of androgen synthesis
inhibition with ketoconazole, hydrocortisone, and dutasteride in asymp-
tomatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:
7099–7105.
20 Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells
during androgen deprivation: Hormone-independent growth, repression of
proliferation by androgen, and role for p27Kip1 in androgen-induced cell
cycle arrest. Mol Endocrinol 1998;12:941–953.
21 Morris MJ, Huang D, Kelly WK et al. Phase 1 trial of high-dose exogenous
testosterone in patients with castration-resistant metastatic prostate cancer.
Eur Urol 2009;56:237–244.
22 Trauger R, Corey E, Bell D et al. Inhibition of androstenediol-dependent
LNCaP tumour growth by 17-ethynyl-5-androstane-3,1 7 -diol
(HE3235). Br J Cancer 2009;100:1068–1072.
23 Montgomery RB, Morris MJ, Ryan CJ et al. HE3235, a synthetic adrenal
hormonedisease-modifyingagent,incastrateresistantprostatecancer:Re-
sults of phase I/II clinical trial [abstract 4674]. J Clin Oncol 2010;28
(15 suppl):385s.
24 Chang YM, Kung HJ Evans CP. Nonreceptor tyrosine kinases in prostate
cancer. Neoplasia 2007;9:90–100.
25 Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18:1765–
1773.
26 Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease.
Int J Cancer 2009;124:1–6.
27 Tatarov O, Mitchell TJ, Seywright M et al. SRC family kinase activity is
up-regulatedinhormone-refractoryprostatecancer.ClinCancerRes2009;
15:3540–3549.
28 Nam S, Kim D, Cheng JQ et al. Action of the Src family kinase inhibitor,
dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res
2005;65:9185–9189.
29 Park SI, Zhang J, Phillips KA et al. Targeting SRC family kinases inhibits
growthandlymphnodemetastasesofprostatecancerinanorthotopicnude
mouse model. Cancer Res 2008;68:3323–3333.
30 Koreckij T, Nguyen H, Brown LG et al. Dasatinib inhibits the growth of
prostate cancer in bone and provides additional protection from osteolysis.
Br J Cancer 2009;101:263–268.
31 Vandyke K, Dewar AL, Farrugia AN et al. Therapeutic concentrations of
dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009;23:994–997.
32 Yu EY, Wilding G, Posadas E et al. Phase II study of dasatinib in patients
with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;
15:7421–7428.
33 Araujo J, Mathew P, Armstrong AJ et al. Dasatinib and docetaxel combi-
nation treatment for patients with metastatic castration-resistant prostate
cancer:AnalysisofStudyCA180–086[abstract7028].EurJCancer2009;
7:415S.
34 Chang YM, Bai L, Liu S et al. Src family kinase oncogenic potential and
pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27:
6365–6375.
35 Green TP, Fennell M, Whittaker R et al. Preclinical anticancer activity of
the potent, oral Src inhibitor AZD0530. Mol Oncol 2009;3:248–261.
36 Yang JC, Ok JH, Busby JE et al. Aberrant activation of androgen receptor
273 Aggarwal, Ryan
www.TheOncologist.comin a new neuropeptide-autocrine model of androgen-insensitive prostate
cancer. Cancer Res 2009;69:151–160.
37 de Vries TJ, Mullender MG, van Duin MA et al. The Src inhibitor
AZD0530 reversibly inhibits the formation and activity of human oste-
oclasts. Mol Cancer Res 2009;7:476–488.
38 Evans CP, Bai L, Kung H et al. Effect of the specific Src kinase inhibitor
AZD0530 on osteolytic lesions in prostate cancer [abstract 170]. Presented
at the 2008 American Society of Clinical Oncology Genitourinary Cancers
Symposium,SanFrancisco,CA,February14–16,2008.Availableathttp://
www.asco.org/ASCOv2/Meetings/Abstracts, accessed February 8, 2011.
39 Lara PN Jr, Longmate J, Evans CP et al. A phase II trial of the Src-kinase
inhibitor AZD0530 in patients with advanced castration-resistant prostate
cancer:ACaliforniaCancerConsortiumstudy.AnticancerDrugs2009;20:
179–184.
40 Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced pros-
tate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug
Targets 2009;9:237–249.
41 LoPiccoloJ,BlumenthalGM,BernsteinWBetal.TargetingthePI3K/Akt/
mTOR pathway: Effective combinations and clinical considerations. Drug
Resist Updat 2008;11:32–50.
42 Cairns P, Okami K, Halachmi S et al. Frequent inactivation of PTEN/
MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997–5000.
43 Pesche S, Latil A, Muzeau F et al. PTEN/MMAC1/TEP1 involvement in
primary prostate cancers. Oncogene 1998;16:2879–2883.
44 McMenamin ME, Soung P, Perera S et al. Loss of PTEN expression in par-
affin-embeddedprimaryprostatecancercorrelateswithhighGleasonscore
and advanced stage. Cancer Res 1999;59:4291–4296.
45 Shen MM, bate-Shen C. Pten inactivation and the emergence of androgen-
independent prostate cancer. Cancer Res 2007;67:6535–6538.
46 Jiao J, Wang S, Qiao R et al. Murine cell lines derived from Pten null pros-
tate cancer show the critical role of PTEN in hormone refractory prostate
cancer development. Cancer Res 2007;67:6083–6091.
47 SchmitzM,GrignardG,MargueCetal.CompletelossofPTENexpression
as a possible early prognostic marker for prostate cancer metastasis. Int J
Cancer 2007;120:1284–1292.
48 Yoshimoto M, Cunha IW, Coudry RA et al. FISH analysis of 107 prostate
cancers shows that PTEN genomic deletion is associated with poor clinical
outcome. Br J Cancer 2007;97:678–685.
49 Sircar K, Yoshimoto M, Monzon FA et al. PTEN genomic deletion is as-
sociated with p-Akt and AR signalling in poorer outcome, hormone refrac-
tory prostate cancer. J Pathol 2009;218:505–513.
50 Morgan TM, Pitts TE, Gross TS et al. RAD001 (everolimus) inhibits
growth of prostate cancer in the bone and the inhibitory effects are in-
creased by combination with docetaxel and zoledronic acid. Prostate 2008;
68:861–871.
51 Ross RW, Beer TM, Jacobus S et al. A phase 2 study of carboplatin plus
docetaxel in men with metastatic hormone-refractory prostate cancer who
are refractory to docetaxel. Cancer 2008;112:521–526.
52 Gross ME, Soscia J, Sakowsky S et al. Phase I trial of RAD001, bevaci-
zumab, and docetaxel for castration-resistant prostate cancer [abstract
5154]. J Clin Oncol 2009;27(15 suppl):272s.
53 George DJ, Armstrong AJ, Creel P et al. A phase II study of RAD001 in
men with hormone-refractory metastatic prostate cancer (HRPC) [abstract
181]. Presented at the 2008 American Society of Clinical Oncology Geni-
tourinary Cancers Symposium, San Francisco, CA, February 14–16, 2008.
Available at http://www.asco.org/ASCOv2/Meetings/Abstracts, accessed
February 8, 2011.
54 WuL,BirleDC,TannockIF.Effectsofthemammaliantargetofrapamycin
inhibitorCCI-779usedaloneorwithchemotherapyonhumanprostatecan-
cer cells and xenografts. Cancer Res 2005;65:2825–2831.
55 Fung AS, Wu L, Tannock IF. Concurrent and sequential administration of
chemotherapy and the mammalian target of rapamycin inhibitor temsiroli-
musinhumancancercellsandxenografts.ClinCancerRes2009;15:5389–
5395.
56 Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian
target of rapamycin inhibitor deforolimus (AP23573; MK-8669) adminis-
teredintravenouslydailyfor5daysevery2weekstopatientswithadvanced
malignancies. J Clin Oncol 2008;26:361–367.
57 Hartford CM, Desai AA, Janisch L et al. A phase I trial to determine the
safety, tolerability, and maximum tolerated dose of deforolimus in patients
with advanced malignancies. Clin Cancer Res 2009;15:1428–1434.
58 Banerji U. Heat shock protein 90 as a drug target: Some like it hot. Clin
Cancer Res 2009;15:9–14.
59 MiyakeH,NelsonC,RenniePSetal.Testosterone-repressedprostatemes-
sage-2 is an antiapoptotic gene involved in progression to androgen inde-
pendence in prostate cancer. Cancer Res 2000;60:170–176.
60 Trougakos IP, So A, Jansen B et al. Silencing expression of the clusterin/
apolipoprotein j gene in human cancer cells using small interfering RNA
induces spontaneous apoptosis, reduced growth ability, and cell sensitiza-
tion to genotoxic and oxidative stress. Cancer Res 2004;64:1834–1842.
61 July LV, Akbari M, Zellweger T et al. Clusterin expression is significantly
enhanced in prostate cancer cells following androgen withdrawal therapy.
Prostate 2002;50:179–188.
62 Chi KN, Eisenhauer E, Fazli L et al. A phase I pharmacokinetic and phar-
macodynamic study of OGX-011, a 2-methoxyethyl antisense oligonucle-
otide to clusterin, in patients with localized prostate cancer. J Natl Cancer
Inst 2005;97:1287–1296.
63 Sowery RD, Hadaschik BA, So AI et al. Clusterin knockdown using the
antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory
prostate cancer PC-3 cells to chemotherapy. BJU Int 2008;102:389–397.
64 Chi KN, Hotte SJ, Yu EY et al. Mature results of a randomized phase II
study of OGX-011 in combination with docetaxel/prednisone versus do-
cetaxel/prednisone in patients with metastatic castration-resistant prostate
cancer [abstract 5012]. J Clin Oncol 2009;27(15 suppl):238s.
65 Werner H, Bruchim I. The insulin-like growth factor-I receptor as an on-
cogene. Arch Physiol Biochem 2009;115:58–71.
66 NickersonT,ChangF,LorimerDetal.InvivoprogressionofLAPC-9and
LNCaP prostate cancer models to androgen independence is associated
with increased expression of insulin-like growth factor I (IGF-I) and IGF-I
receptor (IGF-IR). Cancer Res 2001;61:6276–6280.
67 KruecklSL,SikesRA,EdlundNMetal.Increasedinsulin-likegrowthfac-
tor I receptor expression and signaling are components of androgen-inde-
pendent progression in a lineage-derived prostate cancer progression
model. Cancer Res 2004;64:8620–8629.
68 Ryan CJ, Haqq CM, Simko J et al. Expression of insulin-like growth fac-
tor-1 receptor in local and metastatic prostate cancer. Urol Oncol 2007;25:
134–140.
69 DiGiovanni J, Kiguchi K, Frijhoff A et al. Deregulated expression of insu-
lin-like growth factor 1 in prostate epithelium leads to neoplasia in trans-
genic mice. Proc Natl Acad SciUSA2000;97:3455–3460.
70 LiaoY,AbelU,GrobholzRetal.Up-regulationofinsulin-likegrowthfac-
tor axis components in human primary prostate cancer correlates with tu-
mor grade. Hum Pathol 2005;36:1186–1196.
71 Renehan AG, Zwahlen M, Minder C et al. Insulin-like growth factor
274 CRPC: Targeted Therapies and Individualized Treatment(IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and
meta-regression analysis. Lancet 2004;363:1346–1353.
72 LuD,ZhangH,KooHetal.AfullyhumanrecombinantIgG-likebispecific
antibody to both the epidermal growth factor receptor and the insulin-like
growth factor receptor for enhanced antitumor activity. J Biol Chem 2005;
280:19665–19672.
73 Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the
anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871
in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834–
5840.
74 Higano CS, Yu EY, Whiting SH et al. A phase I, first in man study of
weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1
monoclonal antibody, in patients with advanced solid tumors [abstract
3505]. J Clin Oncol 2007;25(18 suppl):139s.
75 Tolcher AW, Sarantopoulos J, Patnaik A et al. Phase I, pharmacokinetic,
and pharmacodynamic study of AMG 479, a fully human monoclonal an-
tibodytoinsulin-likegrowthfactorreceptor1.JClinOncol2009;27:5800–
5807.
76 Higano C, Alumkal J, Ryan CJ et al. A phase II study evaluating the effi-
cacy and safety of single agent IMC A12, a monoclonal antibody, against
the insulin-like growth factor-1 receptor, as monotherapy in patients with
metastatic, asymptomatic castration-resistant prostate cancer [abstract
5142]. J Clin Oncol 2009;27(27 suppl):269s.
77 Duque JL, Loughlin KR, Adam RM et al. Plasma levels of vascular endo-
thelial growth factor are increased in patients with metastatic prostate can-
cer. Urology 1999;45:523–527.
78 Melnyk O, Zimmerman M, Kim KJ et al. Neutralizing anti-vascular endo-
thelial growth factor antibody inhibits further growth of established pros-
tatecancerandmetastasesinpre-clinicalmodel.JUrol1999;161:960–963.
79 Reese DM, Fratesi P, Corry M et al. A phase II trial of humanized anti-
vascular endothelial growth factor antibody for the treatment of androgen-
independent prostate cancer. Prostate 2001;3:65–70.
80 Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, pla-
cebo-controlled phase III trial comparing docetaxel, prednisone, and pla-
cebo with docetaxel, prednisone, and bevacizumab in men with metastatic
castration-resistant prostate cancer (mCRPC): Survival results of CALGB
90401. J Clin Oncol 2010;28(28 suppl):LBA4511.
81 Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic
castration-resistant prostate cancer following docetaxel-based chemother-
apy. Ann Oncol 2010;21:319–324.
82 Levin ER. Endothelins. N Engl J Med 1995;333:356–363.
83 Nelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in
thepathophysiologyofmetastaticadenocarcinomaoftheprostate.NatMed
1995;1:944–949.
84 Nelson JB, Nguyen SH, Wu-Wong JR et al. New bone formation in an os-
teoblastictumormodelisincreasedbyendothelin-1overexpressionandde-
creased by endothelin A receptor blockade. Urology 1999;53:1063–1069.
85 Carducci MA, Padley RJ, Bruel J et al. Effect of endothelin-A receptor
blockade with atrasentan on tumor progression in men with hormone-
refractor prostate cancer: A randomized, phase II, placebo-controlled trial.
J Clin Oncol 2003;21:679–689.
86 Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized con-
trolled trial of the efficacy and safety of atrasentan in men with metastatic
hormone-refractory prostate cancer. Cancer 2007;110:1959–1966.
87 Nelson JB, Chin JL, Love W et al. Results of a phase 3 randomized con-
trolled trial of the safety and efficacy of atrasentan in men with non-
metastatic hormone-refractory prostate cancer (HRPC) [abstract 146].
Presented at the 2007 Prostate Cancer Symposium, Orlando, FL, February
22–24, 2007.
88 Schelman WR, Liu G, Wilding G et al. A phase I study of zibotentan
(ZD4054) in patients with metastatic castrate-resistant prostate cancer. In-
vest New Drugs 2011;29:118–125.
89 James ND, Caty A, Payne H et al. Final safety and efficacy analysis of the
specific endothelin A receptor antagonist zibotentan (ZD4054) in patients
with metastatic castration-resistant prostate cancer and bone metastases
who were pain-free or mildly symptomatic for pain: A double-blind, pla-
cebo-controlled, randomized phase II trial. BJU Int 2010;106:966–973.
90 Palmberg C, Koivisto P, Kakkola L et al. Androgen receptor gene amplifi-
cation at primary progression predicts response to combined androgen
blockade as second line therapy for advanced prostate cancer. J Urol 2000;
164:1992–1995.
91 Mendiratta P, Mostaghel E, Guinney J et al. Genomic strategy for targeting
therapy in castration-resistant prostate cancer. J Clin Oncol 2009;27:2022–
2029.
92 Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human
cancers as a guide to targeted therapies. Nature 2006;439:353–357.
93 Wang XD, Reeves K, Luo FR et al. Identification of candidate predictive
andsurrogatemolecularmarkersfordasatinibinprostatecancer:Rationale
for patient selection and efficacy monitoring. Genome Biol 2007;8:R255.
94 LaTulippe E, Satagopan J, Smith A et al. Comprehensive gene expression
analysis of prostate cancer reveals distinct transciptional programs associ-
ated with metastatic disease. Cancer Res 2002;62:4499–4506.
95 Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating
tumour cells in cancer patients by microchip technology. Nature 2007;450:
1235–1239.
96 de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells pre-
dict survival benefit from treatment in metastatic castration-resistant pros-
tate cancer. Clin Cancer Res 2008;14:6302–6309.
97 RossRW,OhWK,XieWetal.Inheritedvariationintheandrogenpathway
isassociatedwiththeefficacyofandrogen-deprivationtherapyinmenwith
prostate cancer. J Clin Oncol 2008;26:842–847.
98 SissungTM,BaumCE,DeekenJetal.ABCB1geneticvariationinfluences
the toxicity and clinical outcome of patients with androgen-independent
prostate cancer treated with docetaxel. Clin Cancer Res 2008;14:4543–
4549.
99 SissungTM,DanesiR,PriceDKetal.AssociationoftheCYP1B1*3allele
withsurvivalinpatientswithprostatecancerreceivingdocetaxel.MolCan-
cer Ther 2008;7:19–26.
275 Aggarwal, Ryan
www.TheOncologist.com